10.87
-0.31(-2.77%)
Currency In USD
| Previous Close | 11.18 |
| Open | 11.52 |
| Day High | 12.48 |
| Day Low | 10.82 |
| 52-Week High | 12.48 |
| 52-Week Low | 3.25 |
| Volume | 2.86M |
| Average Volume | 1.31M |
| Market Cap | 921.73M |
| PE | -20.9 |
| EPS | -0.52 |
| Moving Average 50 Days | 7.73 |
| Moving Average 200 Days | 5.65 |
| Change | -0.31 |
If you invested $1000 in Anavex Life Sciences Corp. (AVXL) 10 years ago, it would be worth $14,689.19 as of December 26, 2024 at a share price of $10.87. Whereas If you bought $1000 worth of Anavex Life Sciences Corp. (AVXL) shares 5 years ago, it would be worth $3,896.06 as of December 26, 2024 at a share price of $10.87.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
GlobeNewswire Inc.
Dec 23, 2024 12:30 PM GMT
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative
Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease
GlobeNewswire Inc.
Dec 23, 2024 12:00 PM GMT
Blarcamesine: Potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Submission based on favorable ANAVEX®2-73-AD-004 trial results in patients with early Alzheimer’s disease Once daily oral admi
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024
GlobeNewswire Inc.
Dec 16, 2024 12:30 PM GMT
Webcast and Conference Call To be Held Monday, December 23, 2024, 8:30 am ETNEW YORK, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on dev